Warberg Asset Management’s ZyVersa Therapeutics ZVSA Stock Holding History

Warberg Asset Management’s Portfolio ZVSA Stock Details ZVSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-34	Closed	-$120K	–	301
2022 Q3	$120K	Hold	34	–	–	0.02%	144
2022 Q2	$119K	Hold	34	–	–	0.03%	117
2022 Q1	$119K	Buy	+34	New	+$118K	0.02%	122

Other funds holding ZVSA

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

Warberg Asset Management's ZVSA Position: Q4 2022 in Review

Warberg Asset Management sold out of ZyVersa Therapeutics (ZVSA) in Q4 2022, closing a stake of 34 shares — an estimated $120K sold.

Warberg Asset Management first reported a position in ZVSA in Q1 2022 and held it in 3 quarters. The position peaked at $120K in Q3 2022. 2 funds tracked by Wall St. Rank hold ZVSA as of Q4 2022.

Warberg Asset Management reported no remaining ZyVersa Therapeutics position as of Q4 2022 after selling out during the quarter.
Warberg Asset Management sold 34 ZyVersa Therapeutics shares in Q4 2022, an estimated $120K.
Warberg Asset Management first reported a position in ZyVersa Therapeutics in Q1 2022 and held it in 3 quarters.
Warberg Asset Management's ZyVersa Therapeutics position peaked at $120K in Q3 2022.
2 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2022.

Based on Warberg Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.